首页> 外文期刊>Current opinion in lipidology >A potential role for monoclonal antibodies in clinical lipidology: Can we look beyond statins?
【24h】

A potential role for monoclonal antibodies in clinical lipidology: Can we look beyond statins?

机译:单克隆抗体在临床脂质学中的潜在作用:我们能否超越他汀类药物?

获取原文
获取原文并翻译 | 示例
           

摘要

Since their introduction into clinical practice in 1986, monoclonal antibodies (mAbs) have rapidly evolved as an established form of therapy for a wide array of clinical conditions, ranging from carcinomas (colorectal carcinoma, chronic lymphocytic leukaemia, malignant melanoma), autoimmune/ rheumatological disorders (systemic lupus erythe-matosis, rheumatoid arthritis, ankylosing spondyli-tis) and bone disease (osteoporosis) [1-5]. These bio-therapeutic agents offer significant advantages over conventional pharmacotherapy in terms of potency and specificity for the target tissue. Although the initial mAbs were developed from mouse hybridoma cell lines which led to hypersensitivity reactions and poor target organ specificity, advances in molecular biology have resulted in the development of chimeric and purely humanized mAbs which are potent, target-specific and have better tolerability [6].
机译:自从1986年被引入临床实践以来,单克隆抗体(mAb)迅速发展成为一种针对多种临床疾病的既定治疗形式,包括癌症(大肠癌,慢性淋巴细胞性白血病,恶性黑色素瘤),自身免疫/风湿病(系统性红斑狼疮,类风湿性关节炎,强直性脊柱炎)和骨病(骨质疏松症)[1-5]。就靶组织的效力和特异性而言,这些生物治疗剂提供了优于常规药物治疗的显着优势。尽管最初的单克隆抗体是从小鼠杂交瘤细胞系中产生的,可导致超敏反应和较差的靶器官特异性,但分子生物学的进步已导致嵌合和纯人源化单克隆抗体的开发,这些单克隆抗体具有较强的针对性,特异性和耐受性[6] ]。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号